Clearpoint neuro congratulates partner aspen neuroscience on use of the clearpoint® navigation system for all enrolled patients in aspiro clinical trial

Solana beach, calif., june 20, 2024 (globe newswire) -- clearpoint neuro, inc. (nasdaq: clpt) (the “company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner aspen neuroscience, inc. on use of the clearpoint neuro navigation system to transplant dopaminergic neuron precursor cells (danpcs) for all enrolled patients with parkinson's disease (pd) in its recently launched aspiro phase 1/2a clinical trial.
ASPU Ratings Summary
ASPU Quant Ranking